[
  {"BODY_SYS1":"Cardiac disorders",
  "CUMM_FATAL_CASELIST13":"null",
  "CUMM_FATAL_COUNT4":"0",
  "CUMM_SERIOUS_CASELIST15":"(100356,2),(100365,2)",
  "CUMM_SERIOUS_COUNT6":"2",
  "CUMM_SPON_CASELIST19":"(100356,2),(100365,2)",
  "CUMM_SPON_COUNT10":"2",
  "CUMM_STUDY_CASELIST17":"null",
  "CUMM_STUDY_COUNT8":"0",
  "INC_TERM2":"Heart attack",
  "NEW_FATAL_CASELIST12":"null",
  "NEW_FATAL_COUNT3":"0",
  "NEW_SERIOUS_CASELIST14":"(100356,2),(100365,2)",
  "NEW_SERIOUS_COUNT5":"2",
  "NEW_SPON_CASELIST18":"(100356,2),(100365,2)",
  "NEW_SPON_COUNT9":"2",
  "NEW_STUDY_CASELIST16":"null",
  "NEW_STUDY_COUNT7":"0",
  "PRODUCT_NAME0":"IBUPROFEN",
  "PRR_VALUE11":"6.5"
  },
  {
    "BODY_SYS1":"Vascular disorders",
    "CUMM_FATAL_CASELIST13":"(100217,1)",
    "CUMM_FATAL_COUNT4":"1",
    "CUMM_SERIOUS_CASELIST15":"(100217,1)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100217,1)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Hypovolaemic shock",
    "NEW_FATAL_CASELIST12":"(100217,1)",
    "NEW_FATAL_COUNT3":"1",
    "NEW_SERIOUS_CASELIST14":"(100217,1)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100217,1)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"0"
  },
  {"BODY_SYS1":"Endocrine disorders",
    "CUMM_FATAL_CASELIST13":"(100217,1)",
    "CUMM_FATAL_COUNT4":"1",
    "CUMM_SERIOUS_CASELIST15":"(100217,1)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100217,1)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Adrenal insufficiency",
    "NEW_FATAL_CASELIST12":"(100217,1)",
    "NEW_FATAL_COUNT3":"1",
    "NEW_SERIOUS_CASELIST14":"(100217,1)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100217,1)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"0"
  },
  { "BODY_SYS1":"Psychiatric disorders",
    "CUMM_FATAL_CASELIST13":"(100217,1)",
    "CUMM_FATAL_COUNT4":"1",
    "CUMM_SERIOUS_CASELIST15":"(100217,1)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100217,1)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Suicidal behaviour",
    "NEW_FATAL_CASELIST12":"(100217,1)",
    "NEW_FATAL_COUNT3":"1",
    "NEW_SERIOUS_CASELIST14":"(100217,1)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100217,1)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"0"
    },
    {"BODY_SYS1":"Gastrointestinal disorders",
    "CUMM_FATAL_CASELIST13":"(100275,2)",
    "CUMM_FATAL_COUNT4":"1",
    "CUMM_SERIOUS_CASELIST15":"(100275,2)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100275,2)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Nausea",
    "NEW_FATAL_CASELIST12":"(100275,2)",
    "NEW_FATAL_COUNT3":"1",
    "NEW_SERIOUS_CASELIST14":"(100275,2)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100275,2)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"6.5"
    },
    {"BODY_SYS1":"Infections and infestations",
    "CUMM_FATAL_CASELIST13":"null",
    "CUMM_FATAL_COUNT4":"0",
    "CUMM_SERIOUS_CASELIST15":"(100365,2)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100365,2)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Acute sinusitis",
    "NEW_FATAL_CASELIST12":"null",
    "NEW_FATAL_COUNT3":"0",
    "NEW_SERIOUS_CASELIST14":"(100365,2)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100365,2)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"0"
    },
    {"BODY_SYS1":"Metabolism and nutrition disorders",
    "CUMM_FATAL_CASELIST13":"(100217,1)",
    "CUMM_FATAL_COUNT4":"1",
    "CUMM_SERIOUS_CASELIST15":"(100217,1)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100217,1)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Hypernatraemia",
    "NEW_FATAL_CASELIST12":"(100217,1)",
    "NEW_FATAL_COUNT3":"1",
    "NEW_SERIOUS_CASELIST14":"(100217,1)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100217,1)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"0"
    },
    {"BODY_SYS1":"Metabolism and nutrition disorders",
    "CUMM_FATAL_CASELIST13":"(100217,1)",
    "CUMM_FATAL_COUNT4":"1",
    "CUMM_SERIOUS_CASELIST15":"(100217,1)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100217,1)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Metabolic acidosis",
    "NEW_FATAL_CASELIST12":"(100217,1)",
    "NEW_FATAL_COUNT3":"1",
    "NEW_SERIOUS_CASELIST14":"(100217,1)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100217,1)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"13"
    },
    {"BODY_SYS1":"Skin and subcutaneous tissue disorders",
    "CUMM_FATAL_CASELIST13":"(100275,2)",
    "CUMM_FATAL_COUNT4":"1",
    "CUMM_SERIOUS_CASELIST15":"(100223,1),(100364,1),(100280,3),(100275,2),(100363,1)",
    "CUMM_SERIOUS_COUNT6":"5",
    "CUMM_SPON_CASELIST19":"(100363,1),(100364,1),(100280,3),(100275,2)",
    "CUMM_SPON_COUNT10":"4",
    "CUMM_STUDY_CASELIST17":"(100223,1)",
    "CUMM_STUDY_COUNT8":"1",
    "INC_TERM2":"Rash",
    "NEW_FATAL_CASELIST12":"(100275,2)",
    "NEW_FATAL_COUNT3":"1",
    "NEW_SERIOUS_CASELIST14":"(100223,1),(100364,1),(100280,3),(100275,2),(100363,1)",
    "NEW_SERIOUS_COUNT5":"5",
    "NEW_SPON_CASELIST18":"(100363,1),(100364,1),(100280,3),(100275,2)",
    "NEW_SPON_COUNT9":"4",
    "NEW_STUDY_CASELIST16":"(100223,1)",
    "NEW_STUDY_COUNT7":"1",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"3.42"
    },
    {"BODY_SYS1":"Congenital, familial and genetic disorders",
    "CUMM_FATAL_CASELIST13":"null",
    "CUMM_FATAL_COUNT4":"0",
    "CUMM_SERIOUS_CASELIST15":"(100292,1)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100292,1)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Brittle bone disease",
    "NEW_FATAL_CASELIST12":"null",
    "NEW_FATAL_COUNT3":"0",
    "NEW_SERIOUS_CASELIST14":"(100292,1)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100292,1)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"0"
    },
    {"BODY_SYS1":"Injury, poisoning and procedural complications",
    "CUMM_FATAL_CASELIST13":"(100217,1)",
    "CUMM_FATAL_COUNT4":"1",
    "CUMM_SERIOUS_CASELIST15":"(100217,1)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100217,1)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Intentional overdose",
    "NEW_FATAL_CASELIST12":"(100217,1)",
    "NEW_FATAL_COUNT3":"1",
    "NEW_SERIOUS_CASELIST14":"(100217,1)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100217,1)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"0"
    },
    {"BODY_SYS1":"Injury, poisoning and procedural complications",
    "CUMM_FATAL_CASELIST13":"(100217,1)",
    "CUMM_FATAL_COUNT4":"1",
    "CUMM_SERIOUS_CASELIST15":"(100217,1)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100217,1)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Toxicity to various agents",
    "NEW_FATAL_CASELIST12":"(100217,1)",
    "NEW_FATAL_COUNT3":"1",
    "NEW_SERIOUS_CASELIST14":"(100217,1)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100217,1)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"0"
    },
    {"BODY_SYS1":"General disorders and administration site conditions",
    "CUMM_FATAL_CASELIST13":"null",
    "CUMM_FATAL_COUNT4":"0",
    "CUMM_SERIOUS_CASELIST15":"(100356,2),(100363,1)",
    "CUMM_SERIOUS_COUNT6":"2",
    "CUMM_SPON_CASELIST19":"(100356,2),(100363,1)",
    "CUMM_SPON_COUNT10":"2",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Fever",
    "NEW_FATAL_CASELIST12":"null",
    "NEW_FATAL_COUNT3":"0",
    "NEW_SERIOUS_CASELIST14":"(100356,2),(100363,1)",
    "NEW_SERIOUS_COUNT5":"2",
    "NEW_SPON_CASELIST18":"(100356,2),(100363,1)",
    "NEW_SPON_COUNT9":"2",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"1.3"
    },
    {"BODY_SYS1":"General disorders and administration site conditions",
    "CUMM_FATAL_CASELIST13":"null",
    "CUMM_FATAL_COUNT4":"0",
    "CUMM_SERIOUS_CASELIST15":"(100292,1)",
    "CUMM_SERIOUS_COUNT6":"1",
    "CUMM_SPON_CASELIST19":"(100292,1)",
    "CUMM_SPON_COUNT10":"1",
    "CUMM_STUDY_CASELIST17":"null",
    "CUMM_STUDY_COUNT8":"0",
    "INC_TERM2":"Oedema",
    "NEW_FATAL_CASELIST12":"null",
    "NEW_FATAL_COUNT3":"0",
    "NEW_SERIOUS_CASELIST14":"(100292,1)",
    "NEW_SERIOUS_COUNT5":"1",
    "NEW_SPON_CASELIST18":"(100292,1)",
    "NEW_SPON_COUNT9":"1",
    "NEW_STUDY_CASELIST16":"null",
    "NEW_STUDY_COUNT7":"0",
    "PRODUCT_NAME0":"IBUPROFEN",
    "PRR_VALUE11":"0"
    }
]